Biotech Brief: Global Diabetes Drug Market Could Reach USD 78 Billion By End Of 2026

PALM BEACH, Florida: The global diabetes drugs market size was valued at USD USD 48,753.1 Million in 2018, is projected to reach USD 78,261.7 Million by the end of 2026, exhibiting a CAGR of 6.1pc , according to industry reports.

Rise in obesity, growing adoption of a sedentary lifestyle and an increase in the consumption of unhealthy diet are likely to enhance the prevalence of diabetes which are expected to boost the market during the forecast period.

The report said that (the) accessibility of low-priced Insulin supported by growing investments in R&D is likely to boost the growth of insulin segment in the global diabetes drugs market. Additionally, growing investments in research and development by many government organizations and new product launches by many key players are likely to boost the diabetes drugs market growth during the forecast period.

Active biotech and pharma companies in the markets this week include Genprex, Inc. (NASDAQ GNPX), Tandem Diabetes Care, Inc. (NASDAQ TNDM), Adverum Biotechnologies, Inc. (NASDAQ ADVM), Lineage Cell Therapeutics, Inc. (NYSE LCTX), Eli Lilly and Company (NYSE LLY).

However another report focused on the rise of new treatments. They stated The global diabetes treatment market is undergoing significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. There has been a drastic increase in the incidents of diabetes worldwide, owing to the rising level of sedentary lifestyles and obesity in global population. The sub-markets such the human insulin and analogues are expected to maintain dominance in the overall diabetes treatment market. The diabetes treatment products include injectable diabetes drugs, oral drugs, insulin therapies, insulin pumps, insulin injection devices and blood glucose monitoring systems. In addition, substantial number of emerging diabetes drugs is under clinical observation by large pharmaceutical companies which are expected to enter the market within the forecast period...

Genprex, Inc. (NASDAQ GNPX) BREAKING NEWS Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes - Genprex (Genprex or the Company), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced that it signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.

The diabetes gene therapy, which was developed by lead researcher and Harvard graduate, Dr. George Gittes, at the Rangos Research Center at UPMC Children's Hospital of Pittsburgh, works by reprogramming beta cells in the pancreas to restore their function, thereby replenishing levels of insulin. The novel infusion process uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The proteins these genes express transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

The diabetes gene therapy has been tested in vivo in mice and nonhuman primates. In studies of diabetic mice, the gene therapy approach restored normal blood glucose levels for an extended period of time, typically around four months. According to Dr. Gittes, the duration of restored blood glucose levels in mice could translate to decades in humans. Following preclinical studies, Dr. Gittes and his team plan to begin a Phase I clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.

One of the biggest advantages of this gene therapy is that it could eliminate the need for insulin replacement therapy for diabetic patients, said Dr. Gittes. Lifting this huge burden for the millions of patients who must continuously monitor blood glucose levels and inject insulin daily would be a breakthrough in modern medicine. This therapy has the potential to truly disrupt the diabetes market.

Genprex will add this exciting technology to its research and development pipeline, diversifying its portfolio and expanding its clinical development programs. The company will continue its focus on developing its immunogene therapies for cancer, including Oncoprex immunogene therapy, its lead drug candidate for non-small cell lung cancer, in parallel with development of the new diabetes gene therapy.

We are excited to announce the licensing agreement with The University of Pittsburgh, and we look forward to working with Dr. Gittes and his team to develop this groundbreaking treatment for diabetes, said Rodney Varner, Genprex's Chairman and Chief Executive Officer. At Genprex, we have always put patient needs first, focusing on ways to bring new treatment options to patient populations who have large unmet medical needs. We believe this diabetes gene therapy may potentially become a new treatment option for the millions of diabetes patients who now must take insulin replacement therapy, and it may be effective for patients who do not benefit sufficiently from that therapy. Even more moving, the diabetes gene therapy could hold the potential to provide long term effectiveness, or even be a cure, for diabetes patients. Read this and more news for GNPX at https//www.financialnewsmedia.com/news-gnpx/
(PRN)

Like This Article?
Biotech Brief: Global Diabetes Drug Market Could Reach USD 78 Billion By End Of 2026